Analysis of carcinogenic risk and dynamics of population morbidity and mortality in the Irkutsk region due to malignant neoplasms

View or download the full article: 
PDF icon health-risk-analysis-2023-3-4.pdf
UDC: 
314.42:616-006.04
DOI: 
10.21668/health.risk/2023.3.04.eng
Authors: 

I.G. Zhdanova-Zaplesvichko1,2, N.V. Efimova3, D.F. Savinykh1, М.F. Savchenkov4

Organization: 

1 Federal Service for Surveillance over Consumer Rights Protection and Human Well-being, Irkutsk regional office, 8 Karla Marksa Str., Irkutsk, 664003, Russian Federation
2Irkutsk State Medical Academy of Postgraduate Education – the branch of the Russian Medical Academy for Continuous Occupational Education, 100 Yubileinyi microdistrict, Irkutsk, 664049, Russian Federation
3East-Siberian Institute of Medical and Ecological Research, 3 12a microdistrict, Angarsk, 665827, Russian Federation
4Irkutsk State Medical University, 1 Krasnogo Vosstaniya Str., Irkutsk, 664003, Russian Federation

Abstract: 

Morbidity and mortality caused by malignant neoplasms (MNs) is a priority challenge for health care.

We analyzed some rough and standardized levels (oncological morbidity and mortality) over 2009–2018 based on official statistics. We ranked the RF regions as per the standardized morbidity level and established that the Irkutsk region took the 1st rank place among 85 RF regions as per it; it took the 16th rank place as per the ‘rough’ level. Morbidity and mortality levels that were higher in the Irkutsk region than the national average were established for such localizations as trachea, bronchi and lung cancer; prostate cancer; cervical cancer. The mortality to morbidity ratios were on average equal to 0.45 in the Irkutsk region and 0.49 in the RF as a whole; we identified a certain decrease in them, by 19.3 % and 20.0 % accordingly. We provided evidence of unacceptable individual carcinogenic chemical risk for people in cities with developed chemical industry and non-ferrous metallurgy. High carcinogenic radiation risks were caused by natural radon levels in soils. We calculated some prognostic morbidity and mortality levels: in 2021, the standardized morbidity level would be between 270.9 and 329.8 cases per 100 thousand people; the ‘rough’ level, between 372.7 and 532.4. The ‘rough’ mortality level would be between 220 and 230 cases per 100 thousand people.

We determined some priority tasks for future research aimed at identifying adverse effects produced by environmental factors and lifestyle-related factors as well as some tasks related to developing relevant targeted activities aimed at eliminating and mitigating cancer-inducing exposures.

Keywords: 
carcinogenic risk, morbidity, mortality, malignant neoplasms, population, chemical factor, radiation factor, prognosis
Zhdanova-Zaplesvichko I.G., Efimova N.V., Savinykh D.F., Savchenkov М.F. Analysis of carcinogenic risk and dynamics of population morbidity and mortality in the Irkutsk region due to malignant neoplasms. Health Risk Analysis, 2023, no. 3, pp. 39–48. DOI: 10.21668/health.risk/2023.3.04.eng
References: 
  1. Agovino M., Aprile M.C., Garofalo A., Mariani A. Cancer mortality rates and spillover effects among different areas: A case study in Campania (southern Italy). Soc. Sci. Med., 2018, vol. 204, pp. 67–83. DOI: 10.1016/j.socscimed.2018.03.027
  2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin., 2019, vol. 69, no. 1, pp. 7–34. DOI: 10.3322/caac.21551
  3. Zaridze D.G., Kaprin A.D., Stilidi I.S. Dynamics of morbidity and mortality from malignant tumors in Russia. Voprosy onkologii, 2018, vol. 64, no. 5, pp. 578–591 (in Russian).
  4. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. Geneva, World Health Organization, 2013. Available at: https://world-heart-federation.org/emerging-leaders/wp-content/uploads/s... (April 8, 2023).
  5. Ito K., Miki Y., Suzuki T., McNamara K.M., Sasano H. In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. Endocr. Relat. Cancer, 2016, vol. 23, no. 7, pp. R323–R335. DOI: 10.1530/ERC-15-0470
  6. Backofen R., Engelhardt J., Erxleben A., Fallmann J., Grüning B., Ohler U., Rajewsky N., Stadler P.F. RNA-bio-informatics: tools, services and databases for the analysis of RNA-based regulation. J. Biotechnol., 2017, vol. 261, pp. 76–84. DOI: 10.1016/j.jbiotec.2017.05.019
  7. Efimova N.V., Khankhareev S.S., Motorov V.R., Madeeva E.V. Assessment of the carcinogenic risk for the population of Ulan-Ude. Gigiena i sanitariya, 2019, vol. 98, no. 1, pp. 90–93. DOI: 10.18821/0016-9900-2019-98-1-90-93 (in Russian).
  8. Cherrie J.W., Hutchings S., Gorman Ng M., Mistry R., Corden C., Lamb J., Sánchez Jiménez A., Shafrir A. [et al.]. Prioritising action on occupational carcinogens in Europe: a socioeconomic and health impact assessment. Br. J. Cancer., 2017, vol. 117, no. 2, pp. 274–281. DOI: 10.1038/bjc.2017.161
  9. Partovi E., Fathi M., Assari M.J., Esmaeili R., Pourmohamadi A., Rahimpour R. Risk assessment of occupational ex-posure to BTEX in the National Oil Distribution Company in Iran. Chronic Dis. J., 2018, vol. 4, no. 2, pp. 48–55. DOI: 10.22122/cdj.v4i2.223
  10. Sostoyanie onkologicheskoĭ pomoshchi naseleniyu Rossii v 2018 godu [The state of oncological care for the population of Russia in 2018]. In: A.D. Kaprin, V.V. Starinskii, G.V. Petrova eds. Moscow, MNIOI im. P.A. Gertsena Publ., 2019, 236 p. (in Russian).
  11. Tursunzade R. An evaluation of the prevalence of malignant neoplasms in Russia using an incidence-mortality model. Demograficheskoe obozrenie, 2018, vol. 5, no. 3, pp. 103–126 (in Russian).
  12. Choynzonov E.L., Zhuikova L.D., Ananina O.A., Odinstova I.N., Valkov M.Yu., Pikalova L.V. Epidemiology of ma-lignant neoplasms in the main cities of the Siberian federal district. Ekologiya cheloveka, 2020, no. 11, pp. 53–59. DOI: 10.33396/1728-0869-2020-11-53-59 (in Russian).
  13. Choynzonov E.L., Zhuikova L.D., Ananina O.A., Odinstova I.N., Pikalova L.V. Lung cancer in the Tomsk region (epidemiological aspects). Sovremennaya onkologiya, 2019, vol. 21, no. 2, pp. 6–9. DOI: 10.26442/18151434.2019.2.190413 (in Russian).
  14. Egorkina A.V., Yamshchikov A.S. Risk factors for noncommunicable diseases and a set of organizational and infra-structural measures for the primary prevention of cancer in the Krasnoyarsk territory. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii, 2019, no. 7, pp. 41–45. DOI: 10.17513/mjpfi.12796 (in Russian).
  15. Zhuikova L.D., Choynzonov E.L., Ananina O.A., Odintsova I.N. Cancer incidence in Siberia and Russian far east. Sibirskii onkologicheskii zhurnal, 2019, vol. 18, no. 6, pp. 5–11 (in Russian).
  16. Merabishvili V.M. List of reasons for changing the system of state reporting of oncological service. Voprosy onkologii, 2018, vol. 64, no. 3, pp. 445–452 (in Russian).
  17. Zaridze D.G., Maksimovich D.M. Prevention of malignant neoplasms. Uspekhi molekulyarnoi onkologii, 2017, vol. 4, no. 2, pp. 8–25. DOI: 10.17650/2313-805X-2017-4-2-8-25 (in Russian).
  18. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, vol. 388, no. 10053, pp. 1659–1724. DOI: 10.1016/S0140-6736(16)31679-8
  19. Aksenova I.A., Domozhirova A.S., Novikova T.S. Trends in the incidence and mortality rates of malignant lung tumors in the population of the south Urals, a large industrial region. Onkologiya. Zhurnal im. P.A. Gertsena, 2017, vol. 6, no. 3, pp. 48–51. DOI: 10.17116/onkolog20176348-51 (in Russian).
  20. Petrova G.V., Starinskiy V.V., Gretsova O.P. Assessment of the quality of accounting of deaths of patients with ma-lignant neoplasms in Russia. Issledovaniya i praktika v meditsine, 2016, vol. 3, no. 4, pp. 70–74. DOI: 10.17709/2409-2231-2016-3-4-8 (in Russian).
Received: 
03.04.2023
Approved: 
06.09.2023
Accepted for publication: 
20.09.2023

You are here

Home